Bacteria, phages and septicemia

PLoS ONE

Volumn 2, Issue 11, 2007, Pages

  Gaidelyté, Aušra ^a   Vaara, Martti ^b   Bamford, Dennis H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C;

ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROPHAGE; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; ULTRAVIOLET RADIATION; VIROGENESIS; VIRUS DETECTION; VIRUS ISOLATION; VIRUS TITRATION; BACTERIAL PHENOMENA AND FUNCTIONS; ELECTRON MICROSCOPY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY;

BACTERIA (MICROORGANISMS);

BACTERIAL PHYSIOLOGY; BACTERIOPHAGES; HUMANS; MICROSCOPY, ELECTRON; SEPSIS;

EID: 42649109060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001145     Document Type: Article

References (23)

1. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885-891.
2. Heymann DL (2006) Resistance to anti-infective drugs and the threat to public health. Cell 124: 671-675.
3. Alekshun MN, Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell 128: 1037-1050.
4. Jikia D, Chkhaidze N, Imesdashvili E, Mgaloblishvili T, Tsitlanadze G et al (2005) The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr9O. Clin Exp Dermatol 30: 23-26.
5. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, et al. (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enteroccus faecium. Infect Immun 70: 204-210.
6. Sulakvelidze A (2005) Phage thqrapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today 10: 807-809.
7. Sulakvelidze A, Kutter E (2005) Bacteriophage therapy in humans. In: Kutter E, Sulakve1idze A, eds. Bacteriophages: Biology and Application. Boca Raton: CRC Press. lip 381-436.
8. Alisky J, Iczkowski K, Rapoport A, Troitsky N (1998) Bacteriopoges show promise as antimicrobial agents. J Infect 36: 5-15.
9. U.S. Food and Drug Administration. FDA Approval bf Listeria-specific Bacteriophage Preparation on Ready-to-Eat (RTE) Meat and Poultry Products. Available at: http://www.cfsan.fda.gov/~dms/opabacqa.html Accessed 6 June 2007.
10. Loeffler JM, Nelson D, Fischetti VA (2001) Rapid killing Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294: 2170-2172.
11. Schuch R, Nelson D, Fischeni VA (2002) A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418: 884-889.
12. Boyd EF (2005) Bacteriophages and bacterial virulence. In: Kutter E, Sulakvelidze A, eds. Bacteriophages: Biology and Application. Boca Raton: CRC Press. pp 223-265.
13. Casjens S (2003) Prophages and bacterial genomics: what have we learned so far? Mol Microbiol 49: 277-300.
14. Canchaya C, Fournous G, Brüssow H (2004) The impact of prophages on bacterial chromosomes. Mol Microbiol 53: 9-18.
15. Boyd EF, Brüssow H (2002) Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol 10: 521-9.
16. Goerke Ch, Köller J, Wolz Ch (2006) Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 50: 171-77.
17. Matsushiro A, Sato K, Miyamoto H, Yamamura T, Honda T (1999) Induction of prophages of enterohemorrhagic Escherichia coli O 157:H7 with norfloxacin. J Bacteriol 181: 2257-2260.
18. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MR, et al. (2000) Quinolone antibiotics induce shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 181: 664-670.
19. Teel LD, Melton-Celsa AR, Schmitt CK, O'Brien AD (2002) One of two copies of the gene for die activatable shiga toxin type 2d in Escherichia coli O91:H21 strain B2F1 is associated with an inducible bacteriophage. Infect Immun 70: 4282-4291.
20. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342: 1930-1936.
21. Loeffler JM, Fischetti VA (2006.) Lysogeny of Streptococus pneumoniae with MM1 phage: Improved adherence and other phenotypic changes. Infect Immun 74: 4486-4495.
22. Bamford JK, Bamford DH (1991) Large-scale purification of membrane- containing bacteriophage PRD1 and its subviral particles. Virology 181: 348-352.
23. Olkkonen VM, Bamford DH (1989) Quantitation of the adsorption and penetration stages of bacteriophage φ6 infection. Virology 171: 229-238.